Sta znaci na Engleskom REZISTENCIJOM - prevod na Енглеском

• resistance

Примери коришћења Rezistencijom на Хрватском и њихови преводи на Енглески

EVOTAZ je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih osoba zaraženih virusom HIV-1 bez poznatih mutacija povezanih s rezistencijom na atazanavir vidjeti dijelove 4.4 i 5.1.
EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir see sections 4.4 and 5.1.

Ako izolati s višim MIK-om dalbavancina predstavljaju stabilne fenotipove i povezani su s rezistencijom na druge glikopeptide, tada bi vjerojatan mehanizam mogao biti porast broja glikopeptidnih ciljeva u nastajućem peptidoglikanu.
If the isolates with higher dalbavancin MICs represent stable phenotypes and are correlated with resistance to the other glycopeptides, then the likely mechanism would be an increase in the number of glycopeptide targets in nascent peptidoglycan.

Do neinfekcije mogu dovesti faktori poput općeg zdravlja i priladnog imunosnog funkcioniranja, stečene imunosti iz prethodne izloženosti ili vakcinaciji, ili genetička imunost kao što je to slučaj s rezistencijom na malariju koja se prenosi barem jednim alelom za srpaste stanice.
Noninfection may be due to such factors as general health and proper immune functioning; acquired immunity from previous exposure or vaccination; or genetic immunity, as with the resistance to malaria conferred by possessing at least one sickle cell allele.

U bolesnika s ekstenzivnom rezistencijom na lijek, kada se smatra da je SIRTURO potrebno uzimati duže od 24 tjedna da bi se postigao kurativni učinak liječenja, duže trajanje liječenja može se uzeti u obzir samo od slučaja do slučaja te uz brižan nadzor sigurnosti vidjeti dijelove 4.4 i 4.8.
In patients with extensive drug resistance, where SIRTURO is considered necessary beyond 24 weeks to obtain a curative treatment, a longer duration of therapy may be considered only on a case by case basis and under close safety surveillance see sections 4.4 and 4.8.

U bolesnika je HIV-1 morao biti stabilno suprimiran(HIV-1 RNK< 50 kopija/ml) početnim reţimom najmanje 6 mjeseci i biti bez mutacija povezanih s rezistencijom na emtricitabin ili tenofoviralafenamid prije ulaska u ispitivanje.
Patients must have been stably suppressed(HIV-1 RNA< 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry.

U panelu od 67 rekombinantnih laboratorijskih sojeva virusa HIV-1 s jednom mutacijom povezanom s rezistencijom na položajima na reverznoj transkriptazi(RT) povezanima s rezistencijom na NNRTI, uključujući najčešće prisutne K103N i Y181C, rilpivirin je pokazao antivirusnu aktivnost na 64(96%) ovih sojeva.
In a panel of 67 HIV-1 recombinant laboratory strains with one resistance-associated mutation at RT positions associated with NNRTI resistance, including the most commonly found K103N and Y181C, rilpivirine showed antiviral activity against 64(96%) of these strains.

Budući da virus hepatitisa B može postati rezistentan na lijek Zeffix, liječnik treba propisati Zeffix samo u slučaju kada nije primjenjivo liječenje za koje je manje vjerojatno da će rezultirati rezistencijom na lijek; dekompenziranom bolešću jetre kada jetra ne funkcionira normalno.
Because the hepatitis B virus can become resistant to Zeffix, the doctor should only consider prescribing Zeffix if other treatments that are less likely to lead to resistance cannot be used; decompensated liver disease when the liver does not work normally.

U panelu sa 67 rekombinantnih laboratorijskih sojeva HIV-1 s jednom mutacijom povezanom s rezistencijom na položajima u RT povezanima s rezistencijom na nenukleozidne inhibitore reverzne transkriptaze, uključujući najčešće pronađene K103N i Y181C, rilpivirin je pokazao antivirusno djelovanje protiv 64(96%) od tih sojeva.
In a panel of 67 HIV-1 recombinant laboratory strains with one resistance-associated mutation at RT positions associated with NNRTI resistance, including the most commonly found K103N and Y181C, rilpivirine showed antiviral activity against 64(96%) of these strains.

U bolesnika koji primaju rilpivirinklorid u kombinaciji s FTC/TDF u ispitivanjima faze 3(objedinjeni podaci TMC278-C209 i TMC278-C215), najveći broj HIV-1 izolata s novonastalom fenotipskom rezistencijom na rilpivirin imalo je križnu rezistenciju na najmanje jedan drugi NNRTI 28/31.
In patients receiving rilpivirine hydrochloride in combination with FTC/TDF in Phase 3 studies(TMC278-C209 and TMC278-C215 pooled data), most HIV-1 isolates with emergent phenotypic resistance to rilpivirine had cross-resistance to at least one other NNRTI 28/31.

Opažene su dvije nove supstitucije na kodonima koje su se prethodno povezivale s rezistencijom na nevirapin: jedan bolesnik s Y181I u skupini na Viramuneu s produljenim oslobađanjem i jedan bolesnik s Y188N u skupini na Viramuneu s trenutnim oslobađanjem; rezistencija na nevirapin potvrđena je fenotipom.
Two new substitutions on codons previously associated with nevirapine resistance were observed: one patient with Y181I in the Viramune prolonged-release group and one patient with Y188N in the Viramune immediate-release group; resistance to nevirapine was confirmed by phenotype.

Tasigna je indicirana za liječenje odraslih bolesnika: s novodijagnosticiranom kroničnom mijeloičnom leukemijom(KML) u kroničnoj fazi s pozitivnim Philadelphia kromosomom, u kroničnoj i ubrzanoj fazi KML-a s pozitivnim Philadelphia kromosomom s rezistencijom ili intolerancijom na prethodno liječenje, uključujući imatinib.
Tasigna is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia(CML) in the chronic phase, chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

Novosti su i preporuke za lijeenje bolesnika u posebnim okolnostima što ukljuuje lijeenje trudnica, bolesnika s rezistencijom na lijekove, bolesnika s koinfekcijama, jetrenom dekompenzacijom, bolesnika na imuno i kemoterapiji i bolesnika nakon transplantacije jetre te bolesnike s HCC.
New findings as well as recommendations for the treatment of patients in special circumstances including treatment of pregnant women, patients with drug resistance, patients with co-infection, hepatic decompensation, patients on immune and chemotherapy, patients after liver transplantation, and patients with HCC will also be included.

Genvoya je indicirana za liječenje odraslih osoba i adolescenata(u dobi od 12 godina i starijih, s tjelesnom težinom od najmanje 35 kg) zaraženih virusom humane imunodeficijencije tipa 1(HIV-1) bez ijedne poznate mutacije povezane s rezistencijom na skupinu inhibitora integraze, emtricitabin ili tenofovir vidjeti dijelove 4.2 i 5.1.
Genvoya is indicated for the treatment of adults and adolescents(aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1(HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir see sections 4.2 and 5.1.

Klinička rezistencija: Pacijenti koji ne odgovaraju na lamivudin i pacijenti koji su nositelji HBV-a s dokazanom rezistencijom na lamivudin( mutacije na rtL180M, rtA181T i/ ili rtM204I/ V) ne smiju biti liječeni monoterapijom adefovirdipivoksila kako bi se smanjio rizik od razvoja rezistencije na adefovir.
Clinical resistance: Lamivudine-refractory patients and patients harbouring HBV with evidence of resistance to lamivudine(mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with adefovir dipivoxil monotherapy in order to reduce the risk of resistance to adefovir.

ODIN je randomizirano, otvoreno ispitivanje faze III u kojem se PREZISTA/ritonavir od 800/100 mg jedanput na dan naspram lijeka PREZISTA/ritonavir od 600/100 mg dva puta na dan u bolesnika prethodno liječenih ART-om inficirani virusom HIV-1, a na probiru pri uključivanju u ispitivanje testiranje genotipa u tih bolesnika nije pokazalo mutacije povezane s rezistencijom na darunavir tj.
ODIN is a Phase III, randomised, open-label trial comparing PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs i.e.

Procjena početnih uzoraka HIV-1 neliječenih bolesnika koji nisu povezani sa supstitucijom aminokiselina povezane s rezistencijom vršila se ili više ciklusnim Virco Antivirogram testom(eng. multi-cycle Virco Antivirogram™ assay)(n=92 u ispitivanju COL40263) ili testom sa jednim ciklusom(Monogram Biosciences PhenoSense™ assay) n=138 u ispitivanju ESS30009.
Baseline HIV-1 samples from therapy-naive subjects with no amino acid substitutions associated with resistance have been evaluated using either the multi-cycle Virco Antivirogram™ assay(n=92 from COL40263) or the the single cycle Monogram Biosciences PhenoSense™ assay n=138 from ESS30009.

Vitekta je indicirana, istovremeno primijenjena s ritonavirom pojačanim inhibitorom proteaze i s drugim antiretrovirusnim lijekovima, za liječenje infekcije virusom humane imunodeficijencije-1( HIV-1) u odraslih koji su zaraženi virusom HIV-1 bez poznatih mutacija povezanih s rezistencijom na elvitegravir vidjeti dijelove 4. 2 i 5. 1.
Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus-1(HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir see sections 4.2 and 5.1.

Eviplera je indicirana za liječenje odraslih pacijenata zaraženih virusom humane imunodeficijencije tipa 1( HIV-1) bez poznatih mutacija povezanih s rezistencijom na klasu nenukleozidnih inhibitora reverzne transkriptaze( NNRTI), tenofovir ili emtricitabin, i virusnim opterećenjem ≤ 100 000 HIV-1 RNK kopija/ ml vidjeti dijelove 4. 2, 4. 4 i 5. 1.
Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1(HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor(NNRTI) class, tenofovir or emtricitabine, and with a viral load≤ 100,000 HIV-1 RNA copies/mL see sections 4.2, 4.4 and 5.1.

Osobito su zabilježeni izvještaji neuspješnog liječenja u bolesnika inficiranih sa Staphylococcus aureus, Enterococcus faecalis ili Enterococcus faecium, uključujući bolesnike s bakterijemijom, a koji su povezani s naknadnom pojavom mikroorganizama sa smanjenom osjetljivošću ili evidentnom rezistencijom na daptomicin tijekom terapije.
In particular, there have been reports of treatment failures in patients infected with Staphylococcus aureus, Enterococcus faecalis or Enterococcus faecium, including bacteraemic patients, that have been associated with the selection of organisms with reduced susceptibility or frank resistance to daptomycin during therapy.

Klinička rezistencija u ispitivanjima gdje je adefovirdipivoksil dodan postojećoj terapiji lamivudinom u pacijenata s rezistencijom na lamivudin: U otvorenom ispitivanju u pacijenata prije i nakon transplantacije jetre s kliničkim dokazanim HBV-om rezistentnim na lamivudin nisu uočene mutacije povezane s rezistencijom na adefovir u 48. tjednu.
Clinical resistance in studies where adefovir dipivoxil was added to ongoing lamivudine in patients with lamivudine-resistance: In an open-label study of pre- and post-liver transplantation patients with clinical evidence of lamivudine-resistant HBV, no adefovir-associated resistance mutations were observed at week 48.

Stribild je indiciran za liječenje odraslih osoba u dobi od 18 godina i više, koje su inficirane virusom humane imunodeficijencije tipa 1( HIV-1) i koje prethodno nisu primale antiretrovirusne lijekove ili su inficirane virusom HIV-1 bez poznatih mutacija povezanih s rezistencijom na bilo koje od tri antiretrovirusne tvari u Stribildu vidjeti dijelove 4. 2, 4. 4 i 5. 1.
Stribild is indicated for the treatment of human immunodeficiency virus-1(HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild see sections 4.2, 4.4 and 5.1.

Ti radiš na rezistenciji na antibiotike kod rastućih mikroorganizama?
You're working on antibiotic resistance in emerging microorganisms?

Ti radiš na rezistenciji na antibiotike kod rastucih mikroorganizama?
In emerging microorganisms? You're working on antibiotic resistance.

Upozorenja Postoji mogućnost rezistenciju i preosjetljivost na drugi tetraciklini.
There is a possibility of cross-resistance and hypersensitivity to other tetracycline drugs.

Do kraja 48. tjedna nije bila otkrivena pojava rezistencije na E/C/F/TAF.
No emergent resistance to E/C/F/TAF was detected through Week 48.

Dodatne zamijećene mutacije koje mogu doprinijeti rezistenciji bile su: L10V/F/R, I13V, K20R/T, L33F/V, M36I, M46I/L, I47V/L Q58E, I62V, L63P, V77I, I85V i I93L.
Additional mutations observed which may contribute to resistance were: L10V/F/R, I13V, K20R/T, L33F/V, M36I, M46I/L, I47V/L Q58E, I62V, L63P, V77I, I85V, and I93L.

Rezistencija na antibiotike je sposobnost rasta bakterija uz prisutnost antibiotika koji bi ih inače ubili ili ograničili njihov rast.
Antibiotic resistance is the ability of bacteria to grow in the presence of an antibiotic that would normally kill them or limit their growth.

Giht, anoreksija, smanjen apetit, smanjena tjelesna težina, povećana tjelesna težina, hiperglikemija, rezistencija na inzulin, sniženi lipoproteini visoke gustoće, povećan apetit, polidipsija, povišena laktat dehidrogenaza u krvi.
Gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase.

Ako imate APC rezistenciju koja je rizični čimbenik za tromboemboliju prisutan u 5% europske populacije, Vaš će liječnik prema tome možda trebati prilagoditi liječenje.
If you have APC resistance which is a thromboembolic risk factor present in up to 5% of the population in Europe your doctor may need to adjust your treatment accordingly.

In vitro: Rezistencija je bila opažena in vitro i u nekih pacijenata zaraženih virusom HIV-1, zbog razvoja mutacije M184V/I uz emtricitabin ili mutacije K65R uz tenofovir.
In vitro: Resistance has been seen in vitro and in some HIV-1 infected patients due to the development of the M184V/I mutation with emtricitabine or the K65R mutation with tenofovir.